QIAGEN N.V.
Financial Report
2022
QIAGEN N.V.
Financial Report
2022
Overview
Management Report
Corporate Governance Report
Environmental, Social
and Governance
Financial Results
Consolidated Financial Statements
Notes to the Consolidated Financial Statements
List of Subsidiaries
Auditor's Report
Appendix
Content
About QIAGEN
4 Introduction
Overview
- Supervisory Board Report
- Executive Committee
- Common Shares
Management Report
- Business and Operating Environment
- Risks Management
95 Critical Accounting Policies, Judgments and Estimates
- Performance Review
- Human Capital
- Outlook
Corporate Governance Report
- Corporate Structure
- Managing Board
- Supervisory Board
124 Diversity within the Management Board and Supervisory Board
124 Compensation of Managing Board Members and Supervisory Directors
129 Additional Information
QIAGEN FINANC IAL REPORT 2022 | 3 |
Environmental, Social and Governance
- Our Approach to Sustainability
- Environmental Responsibility
- Invest in People
- Serving Societies
- Business with Integrity
- EU Taxonomy
- ESG performance at a glance
Financial Results
182 Consolidated Financial Statements
189 Notes to the Consolidated Financial Statements
- List of Subsidiaries
- Auditor's Report
Appendix
- Services
- Imprint
This document contains detailed financial information about QIAGEN prepared under generally accepted accounting standards in the U.S. (U.S. GAAP) and included in our Form 20-F annual report filed with the U.S. Securities and Exchange Commission. QIAGEN also publishes an Annual Report under IFRS accounting standards, which is available on our website at www.QIAGEN.com.
We help advance science and improve outcomes
Our Mission
Enabling access to valuable insights from molecular research to clinical healthcare
Our Vision
Making improvements in life possible
QIAGEN at a glance
Our products support scientists and clinicians to advance scientific discovery and improve patient outcomes
A global company with scaleSales
$2.1 L I S T E D | ~45% | |||
~20% | ||||
QGEN | ||||
billion | EMEA | |||
NYSE | ||||
Americas | ||||
(2022 sales) | ~35% | Asia-Pacific / Japan |
Highly recurring revenues | Balanced customer markets | ||||||
~88 % | ~12 % | ~50% | ~50% | ||||
Consumables | |||||||
and related | Molecular | Life | |||||
revenues | Instruments | Diagnostics | Sciences | ||||
~ 6,200
employees known as QIAGENers
> 500,000
customers worldwide
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Qiagen NV published this content on 10 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2023 07:56:07 UTC.